Short Interest in Evotec SE (NASDAQ:EVO) Rises By 42.0%

Evotec SE (NASDAQ:EVO - Get Free Report) was the recipient of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 271,800 shares, a growth of 42.0% from the August 31st total of 191,400 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 83,900 shares, the short-interest ratio is presently 3.2 days.

Evotec Stock Up 2.3 %

EVO traded up $0.08 during trading on Friday, hitting $3.57. The company had a trading volume of 116,721 shares, compared to its average volume of 107,509. The company has a current ratio of 1.83, a quick ratio of 1.73 and a debt-to-equity ratio of 0.42. Evotec has a 1-year low of $2.85 and a 1-year high of $12.00. The business has a 50-day moving average of $3.68 and a 200-day moving average of $5.02.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Morgan Stanley lowered Evotec from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $15.00 to $6.00 in a research note on Monday, July 29th. Deutsche Bank Aktiengesellschaft lowered shares of Evotec from a "hold" rating to a "sell" rating in a report on Thursday, August 8th. Finally, HC Wainwright cut their target price on Evotec from $11.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday, August 15th.

Hedge Funds Weigh In On Evotec

A number of large investors have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC bought a new stake in Evotec during the second quarter worth approximately $87,000. Cetera Advisors LLC acquired a new stake in Evotec during the first quarter valued at $188,000. DCF Advisers LLC grew its stake in shares of Evotec by 140.5% in the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock valued at $552,000 after buying an additional 67,156 shares in the last quarter. Optiver Holding B.V. raised its holdings in shares of Evotec by 643.1% during the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company's stock valued at $945,000 after purchasing an additional 69,936 shares in the last quarter. Finally, Mubadala Investment Co PJSC bought a new position in shares of Evotec in the 4th quarter valued at approximately $53,931,000. Institutional investors own 5.81% of the company's stock.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.